Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03760237 · ClinicalTrials.gov registry record
Cardiovascular Function in Acute Leukemia
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 84
- Enrollment target
NCT03760237: Completed study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT03760237 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 84 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03760237 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 84 participants
- Enrollment target
Study Summary
An observational, prospective study to describe the rates and predictors of cardiovascular events in patients with acute leukemia.
Primary Outcome
defined as a reduction in Left Ventricular Ejection Fraction of more than 10 percentage points from baseline and to less than 50%.
Interventions
- OTHER observation only
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2018-12-10 |
| Est. Completion | 2024-05-06 |
What the finished NCT03760237 record still lists
NCT03760237 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 84 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which observation only is the first listed.
NCT03760237 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03760237 about?
NCT03760237 is a clinical study titled "Cardiovascular Function in Acute Leukemia". An observational, prospective study to describe the rates and predictors of cardiovascular events in patients with acute leukemia.
What is the current status of trial NCT03760237?
This trial is currently completed. The enrollment target is 84 participants. The study started on 2018-12-10. Estimated completion is 2024-05-06.
What interventions are being tested in trial NCT03760237?
The interventions under investigation include: observation only (OTHER).
Who is sponsoring clinical trial NCT03760237?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI